Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: biotherapeutics - Greenovation Biotech

Next Previous
Drug Profile

Research programme: biotherapeutics - Greenovation Biotech

Alternative Names: Moss-alpha-glucosidase; Moss-factor H; Moss-FH; Moss-GAA; Moss-GBA; Moss-glucerase; Moss-glucocerebrosidase

Latest Information Update: 28 Jun 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Greenovation Biotech
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Alpha-glucosidase replacements; Complement system protein replacements; Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gaucher's disease; Glycogen storage disease type II; Haemolytic uraemic syndrome

Most Recent Events

  • 28 Jun 2020 No recent reports of development identified for preclinical development in Gaucher's-disease in Germany
  • 28 Jun 2020 No recent reports of development identified for preclinical development in Haemolytic-uraemic-syndrome in Germany
  • 28 Jun 2020 No recent reports of development identified for research development in Glycogen-storage-disease-type-II in Germany

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top